Argo Biopharma’s RNAi therapy targets Lp(a): What Phase 2b with Novartis could prove
Novartis advances Argo Biopharma’s BW-20829 into Phase 2b to target lipoprotein(a). Explore what this means for RNAi adoption in cardiovascular therapeutics.
Pharma & Biotech
Pharma & Biotech
Is oral GLP-1 finally viable? Inside Ascletis Pharma’s U.S. trial for ASC30
Ascletis starts U.S. Phase II trial of ASC30 in type 2 diabetes. Find out what this oral GLP-1R agonist could mean for the future of metabolic therapies.
Pharma & Biotech
FDA priority review for Leqembi Iqlik could transform Alzheimer’s drug initiation at home
Leqembi Iqlik gets FDA Priority Review for at-home Alzheimer’s treatment initiation. Find out what this could mean for patients, payers, and the care model.
Pharma & Biotech
Moderna and Merck’s mRNA-4157 combo shows durable benefit in resected high-risk melanoma
Moderna, Inc. and Merck have reported five-year follow-up results from the Phase 2b KEYNOTE-942 study evaluating intismeran autogene (mRNA-4157 or V940), an investigational individualized mRNA-based neoantigen therapy, in combination with pembrolizumab (KEYTRUDA) in patients with resected high-risk stage III or IV melanoma. The combination demonstrated a 49 percent reduction in the risk of recurrence or
Pharma & Biotech
Can J&J’s lumateperone raise the bar for MDD remission? New CAPLYTA data fuels fresh hope
Johnson & Johnson (J&J) has presented new pooled data from Phase 3 clinical trials showing that CAPLYTA (lumateperone), used as an adjunctive therapy with antidepressants, significantly improved remission rates in adults with major depressive disorder compared to placebo. The results, highlighted at the 64th Annual Meeting of the American College of Neuropsychopharmacology, indicate nearly double
Pharma & Biotech
GSK’s Trelegy Ellipta becomes China’s first approved triple therapy for both asthma and COPD
GSK plc has received regulatory approval from China’s National Medical Products Administration (NMPA) to market Trelegy Ellipta, a once-daily inhaled combination of fluticasone furoate, umeclidinium, and vilanterol, for the treatment of adult patients with uncontrolled asthma. This decision expands Trelegy Ellipta’s label beyond its existing indication in chronic obstructive pulmonary disease (COPD), making it the
Pharma & Biotech
NeuroSense expands Alzheimer’s IP with U.S. patent, but all eyes are on RoAD trial results
NeuroSense gains a U.S. patent for PrimeC in Alzheimer’s disease. Find out what it means ahead of key trial results due in early 2026.
Pharma & Biotech
Brello Rise enters the obesity care landscape as a digital wellness adjunct to medical weight loss
Brello Health launches Brello Rise, a digital studio for patients in medical weight loss programs. Find out what this signals for obesity care models.
Pharma & Biotech
Why BioCryst’s Astria acquisition reshapes long-acting competition in hereditary angioedema prophylaxis
BioCryst completes its Astria acquisition to expand long-acting hereditary angioedema leadership. Find out what this means for HAE treatment competition.
Pharma & Biotech
How urcosimod’s FDA compassionate use authorization reshapes development risk in ocular neuropathic pain
FDA allows compassionate use of urcosimod for neuropathic corneal pain. Read how this decision reshapes regulatory, clinical, and development risk.